Sarepta Therapeutics, Inc. (SRPT)
SRPT Stock Price Chart
Explore Sarepta Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze SRPT price movements and trends.
SRPT Company Profile
Discover essential business fundamentals and corporate details for Sarepta Therapeutics, Inc. (SRPT) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
4 Jun 1997
Employees
1.37k
Website
https://www.sarepta.comCEO
Douglas S. Ingram
Description
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
SRPT Financial Timeline
Browse a chronological timeline of Sarepta Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 Aug 2026
EPS estimate is $0.49, while revenue estimate is $382.01m.
Earnings released on 6 May 2026
EPS came in at $3.16 surpassing the estimated $0.98 by +223.77%, while revenue for the quarter reached $730.80m , beating expectations by +54.13%.
Earnings released on 25 Feb 2026
EPS came in at -$3.58 falling short of the estimated -$1.03 by -247.57%, while revenue for the quarter reached $442.93m , beating expectations by +19.84%.
Earnings released on 3 Nov 2025
EPS came in at -$0.13 falling short of the estimated $0.01 by -1.40k%, while revenue for the quarter reached $399.36m , beating expectations by +2.04%.
Earnings released on 6 Aug 2025
EPS came in at $2.02 surpassing the estimated $0.83 by +142.79%, while revenue for the quarter reached $611.09m , beating expectations by +15.16%.
Earnings released on 6 May 2025
EPS came in at -$3.42 falling short of the estimated $0.35 by -1.08k%, while revenue for the quarter reached $744.86m , beating expectations by +0.71%.
Earnings released on 26 Feb 2025
EPS came in at $1.50 surpassing the estimated $1.38 by +8.70%, while revenue for the quarter reached $658.41m , beating expectations by +4.34%.
Earnings released on 6 Nov 2024
EPS came in at $0.62 surpassing the estimated -$0.06 by +1.14k%, while revenue for the quarter reached $467.17m , beating expectations by +14.74%.
Earnings released on 7 Aug 2024
EPS came in at $0.07 surpassing the estimated $0.01 by +1.20k%, while revenue for the quarter reached $362.93m , missing expectations by -7.98%.
Earnings released on 1 May 2024
EPS came in at $0.73 surpassing the estimated $0.10 by +625.65%, while revenue for the quarter reached $413.46m , beating expectations by +8.94%.
Earnings released on 28 Feb 2024
EPS came in at $0.47 surpassing the estimated $0.01 by +3.08k%, while revenue for the quarter reached $396.78m , beating expectations by +2.84%.
Earnings released on 1 Nov 2023
EPS came in at -$0.46 surpassing the estimated -$1.66 by +72.29%, while revenue for the quarter reached $331.82m , missing expectations by -8.63%.
Earnings released on 2 Aug 2023
EPS came in at -$0.27 surpassing the estimated -$1.89 by +85.71%, while revenue for the quarter reached $261.24m , beating expectations by +0.65%.
Earnings released on 2 May 2023
EPS came in at -$0.97 surpassing the estimated -$1.46 by +33.56%, while revenue for the quarter reached $253.50m , beating expectations by +4.77%.
Earnings released on 28 Feb 2023
EPS came in at -$1.24 surpassing the estimated -$1.28 by +3.13%, while revenue for the quarter reached $258.43m , beating expectations by +3.21%.
Earnings released on 2 Nov 2022
EPS came in at -$2.94 falling short of the estimated -$1.21 by -142.98%, while revenue for the quarter reached $230.27m , missing expectations by -1.81%.
Earnings released on 2 Aug 2022
EPS came in at -$2.65 falling short of the estimated -$1.07 by -147.66%, while revenue for the quarter reached $233.49m , beating expectations by +5.74%.
Earnings released on 4 May 2022
EPS came in at -$1.20 surpassing the estimated -$1.35 by +11.11%, while revenue for the quarter reached $210.83m , beating expectations by +2.13%.
Earnings released on 1 Mar 2022
EPS came in at -$1.42 surpassing the estimated -$1.51 by +5.96%, while revenue for the quarter reached $201.46m , beating expectations by +1.76%.
Earnings released on 3 Nov 2021
EPS came in at -$0.60 surpassing the estimated -$1.86 by +67.74%, while revenue for the quarter reached $189.41m , missing expectations by -33.76%.
Earnings released on 4 Aug 2021
EPS came in at -$1.02 surpassing the estimated -$1.03 by +0.97%, while revenue for the quarter reached $164.09m , beating expectations by +0.88%.
SRPT Stock Performance
Access detailed SRPT performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
